Efficacy of Combined SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Managing Diabetic Nephropathy

Authors

  • Jian Zhang Chengdu Medical College, Chengdu, China Author

DOI:

https://doi.org/10.70088/dndqkd52

Keywords:

SGLT2 inhibitors, GLP-1 receptor agonists, diabetic nephropathy, combination therapy, renal function

Abstract

This research article after judge the efficaciousness of commingle SGLT2 inhibitor and GLP-1 receptor agonist therapy in managing nephrosis. The subject investigates the effects of these pharmacological agent on subprogram, glycemic ascendance. And cardiovascular outcome. A comprehensive plan was employed. Include randomize controlled run and statistical analysis. Resolution bespeak important improvements in biomarkers, proteinuria. And enhance glycemic stability equate to monotherapies. The word progressively highlights the likely mechanics underlie these benefits, as amend regularization and -inflammatory effects. In mitigate diabetic nephropathy advancement; this report emphasise the therapeutic hope of combination therapy.

References

R. A. DeFronzo, "Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor," Diabetes Obes. Metab., vol. 19, no. 10, pp. 1353-1362, 2017.

C. Li, J. Luo, M. Jiang, and K. Wang, "The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis," Front. Pharmacol., vol. 13, p. 838277, 2022.

A. Winiarska, M. Knysak, K. Nabrdalik, J. Gumprecht, and T. Stompor, "Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists," Int. J. Mol. Sci., vol. 22, no. 19, p. 10822, 2021.

J. Li, O. Albajrami, M. Zhuo, C. E. Hawley, and J. M. Paik, "Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease," Clin. J. Am. Soc. Nephrol., vol. 15, no. 11, pp. 1678-1688, 2020.

B. L. Neuen, H. J. Heerspink, P. Vart, B. L. Claggett, R. A. Fletcher, C. Arnott, et al., "Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria," Circulation, vol. 149, no. 6, pp. 450-462, 2024.

T. Yamada, M. Wakabayashi, A. Bhalla, N. Chopra, H. Miyashita, T. Mikami, et al., "Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis," Cardiovasc. Diabetol., vol. 20, no. 1, p. 14, 2021.

J. H. Bae, "SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: evolving evidence and clinical application," Diabetes Metab. J., vol. 49, no. 3, pp. 386-402, 2025.

J. M. Colombijn, J. F. de Leijer, F. L. Visseren, M. C. Verhaar, D. H. van Raalte, N. Sattar, et al., "Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies," Diabetologia, pp. 1-14, 2025.

M. Guo, J. Gu, F. Teng, J. Chen, X. Ma, Q. Chen, et al., "The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis," Endocrine, vol. 67, no. 2, pp. 294-304, 2020.

T. Nagahisa and Y. Saisho, "Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes," Diabetes Ther., vol. 10, no. 5, pp. 1733-1752, 2019.

R. S. Busch and M. P. Kane, "Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes," Postgrad. Med., vol. 129, no. 7, pp. 686-697, 2017.

B. L. Neuen, R. A. Fletcher, L. Heath, A. Perkovic, M. Vaduganathan, S. V. Badve, et al., "Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis," Circulation, vol. 150, no. 22, pp. 1781-1790, 2024.

Downloads

Published

07 November 2025

Issue

Vol. 2 No. 4 (2025)

Section

Article

License

Copyright (c) 2025 Jian Zhang (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Zhang, J. (2025) “Efficacy of Combined SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Managing Diabetic Nephropathy”, Medicine Insights, 2(4), pp. 24–35. doi:10.70088/dndqkd52.